General MedicationsNASALStandard
BAQSIMI
GLUCAGON
Standard Dose
3MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview BAQSIMI is listed in Drugs@FDA under application 210134 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient GLUCAGON Form and strength POWDER;NASAL - 3MG Sponsor AMPHASTAR PHARMS INC Submission history Latest submission status date: 2025-03-17 00:00:00.
Structured Monograph
Clinical summary
Approval overview BAQSIMI is listed in Drugs@FDA under application 210134 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient GLUCAGON Form and strength POWDER;NASAL - 3MG Sponsor AMPHASTAR PHARMS INC Submission history Latest submission status date: 2025-03-17 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.